Biosimilars and Bioanalytical Methods

TopicLeading institutions, researchers & key papers

This cluster of papers focuses on the immunogenicity of biosimilar therapeutics, including the validation of bioanalytical methods for assessing immunogenicity, the impact of manufacturing changes on immunogenicity, and the clinical outcomes and safety of switching from reference biologics to biosimilars. The use of dried blood spots for bioanalysis and the regulatory considerations for biosimilars are also prominent topics within this cluster.

142

Works

IDs:OpenAlex

How has Biosimilars and Bioanalytical Methods's publication output changed over time?

ScholarIQpublication output · 2006–2022

Output grew0% over the shown period — from 1 works in 2006 to 1 in 2022.

200620142015201720182022

What are the most-cited papers on Biosimilars and Bioanalytical Methods?

ScholarIQmost cited works

History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology

Kamyar Kalantar‐Zadeh

American Journal of Nephrology. 20171,150 CitationsOPEN ACCESS

A Practical Guide to Immunoassay Method Validation

Ulf Andréasson, Armand Perret‐Liaudet, Linda Josephine Christine van Waalwijk van Doorn, Kaj Blennow, Davide Chiasserini, Sebastiaan Engelborghs, Tormod Fladby, Şermin Genç, Niels Kruse, H. Bea Kuiperij, Luka Kulic, Piotr Lewczuk, Brit Mollenhauer, Barbara Mroczko, Lucilla Parnetti, Eugeen Vanmechelen, Marcel M. Verbeek, Bengt Winblad, Henrik Zetterberg, Marleen J.A. Koel‐Simmelink, Charlotte E. Teunissen

Frontiers in Neurology. 2015551 CitationsOPEN ACCESS

Policies for biosimilar uptake in Europe: An overview

Evelien Moorkens, Arnold G. Vulto, Isabelle Huys, Pieter Dylst, Brian Godman, Simon Keuerleber, Barbara Claus, Maria Dimitrova, Guenka Petrova, Ljiljana Sović-Brkičić, Juraj Slabý, Robin Šebesta, Ott Laius, Allan Karr, M. Beck, Jaana E. Martikainen, Gisbert Selke, Susan Spillane, Laura McCullagh, Gianluca Trifirò, Patricia Vella Bonanno, Asbjørn Mack, Antra Fogele, Anita Viksna, Magdalena Władysiuk, Hélder Mota‐Filipe, Dmitry Meshkov, Marija Kalaba, Simona Mencej Bedrač, Jurij Fürst, Corrine Zara, Peter Skiöld, Einar Magnússon, Steven Simoens

PLoS ONE. 2017353 CitationsOPEN ACCESS

Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab

Lieke Tweehuysen, Bart J. F. van den Bemt, Iris L. van Ingen, Alphons J.L. de Jong, W.H. van der Laan, F.H.J. van den Hoogen, Alfons A den Broeder

Arthritis & Rheumatology. 2017164 Citations

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

Valentin Brodszky, Petra Baji, Orsolya Balogh, Márta Péntek

The European Journal of Health Economics. 2014129 CitationsOPEN ACCESS